गोपनीय : Confidential

मिसिल स.. 8(13)/2014 डी.पी./एन पी पी ए- डीवी-II

F. No. 8(13)/2014/DP/NPPA-Div. II

कार्यवाही स. : 145/13/2014/F

Proceeding No : 145/13/2014/F

Minutes of the 145th and 13th meeting of Authority under DPCO, 2013 held on 1st April, 2014 at 11.00 A.M.

The 145th meeting of the Authority which is 13th under the DPCO, 2013 was held on 1st April, 2014 at 11.00 A.M. under the Chairmanship of Sh. C. P. Singh Chairman, NPPA. The following members of the NPPA were present:-

- (i) Shri A.K. Gautam, Member Secretary Incharge, NPPA.
- (ii) Shri K.L. Prasad, Member (Ex-Officio), Adviser, Economic Division, Deptt. of Economic Affairs.
- (iii) Shri L.M. Kaushal, Director (Cost), Member (Ex-Officio), Deptt. of Expenditure, Ministry of Finance.
- (iii) Shri R. Chandrashekar, Deputy Drug Controller, representing the DCG(I), Department of Health.

The following officers also attended the meeting and assisted the Authority in its deliberations:-

- (i) Shri A.K. Saha, Director (Overcharging)
- (ii) Shri Lal Sanglur, Director (Admin.)
- (iii) Shri Jagdish Kumar, Director (Monitoring)
- (ii) Shri A.K. Khurana, Director (Pricing & OC)
- (iii) Shri S. K. Bhatt, Dy. Director (Technical)
- (iv) Shri Singh Veer Pratap, Dy. Director (Cost)
- (v) Shri G. Pradhan, Dy. Director (Cost)

AL

- (vi) Smt. Manmohan Kaur, Dy. Director (Cost)
- (vii) Shri Manish Goswami, Dy. Director (Cost)
- (viii) Smt. Babita Singh, Asstt. Director (Cost)
- (ix) Shri T. R. Satish Chandran, Asstt. Director (Cost)

Chairman, NPPA welcomed all the members present in the meeting.

- 1. Agenda Item no. 1:
- 1.0 Members of the Authority confirmed the minutes of the meeting.
- 2. Agenda Item no. 2: Action Taken Report:
- 2.0 Noted.
- 3. Agenda Item no. 3:
- 3.0 The Authority discussed the price revision in respect of the two cases based on the representations received from the companies. The details of these cases are as under:-

(i) 5-Amino Salicylic Acid (5-ASA) 400 mg tablets

The Authority discussed the proposal and approved the revised ceiling price of Rs. 8.60/tablet as against the earlier ceiling price of Rs. 3.90/tablet notified vide S.O. 3368(E) on 05.11.2013.

(ii) Promethazine Injection 25mg /ml

The Authority discussed the proposal in detail and approved the revised ceiling price of Rs. 2.99/ml as against the earlier ceiling price of Rs. 2.84/ml notified vide S.O. 424(E) on 17.02.2014. Since the review application is pending with the DOP, therefore,

M

after the notification of the revise ceiling price, the same may be informed to the DOP to dispose of the review case pending with them.

4. Agenda Item no. 4:

- 4.0 The Authority discussed the proposal as per the decision taken in the 144th/12th Authority meeting. Accordingly, where prices were notified only upto 31st May, 2012 under DPCO, 1995 are to be considered for fixation of ceiling price in April, 2014 under DPCO, 2013 and in all other cases where prices were notified after 31st May, 2012, prices in such cases will have to be notified only in April, 2015 or in the month of April of succeeding financial year as the case may be, as per the provisions of Para 10(2) of DPCO, 2013. Therefore, cases where prices were notified upto 31st May, 2012 have been included in the agenda.
- 4.1 It was also informed to the Authority that the price fixation of Ciprofloxacin based formulation is sub-judice under DPCO, 1995 and the case is pending in the Hon'ble Supreme Court. Therefore, price fixation/revision of Ciprofloxacin based formulations was not carried out in DPCO, 1995. The Authority decided that the price fixation of Ciprofloxacin formulations may be carried out in accordance with the provisions of DPCO, 2013.
- 4.2 It was also informed to the Authority that there is a typographical error in the working sheet on the Prednisolone Tablet 10mg and the revised working sheet was circulated to the Authority as well as officers of the NPPA during the meeting. Accordingly, the Authority approved the ceiling price of Rs. 0.92/tablet for Prednisolone tablet 10mg. After discussion, the Authority approved the ceiling prices in all the 15 cases. The details of these cases are encl osed as Annexure-A.

M

. Agenda Item no. 5:

Razo Injection 20mg (Rabeprazole 20mg) vial + Sol 10ml Injection

- 5.0 The Authority discussed the proposal in detail in the background of the provisions provided under DPCO, 1995 as well as DPCO, 2013 and directed that the data of price movement for the last four years in respect of the formulation under reference may be collected and examined by the Div (M&E). Accordingly, the case was deferred. Authority also directed that all such pending cases may be examined and put up in next meeting.
- 6.0 This issues with the approval of Chairman, NPPA.

Member Secretary Incharge

(A.K. Gautam) 01/4/20/

Ceiling price under DPCO 1995 (Exct. E.D.) (Rs) 20.68/10°s At St 3.82/5 ml visi/ Amp 6.96/10's AL ST 1234(E) d. 19 12,2001 9,06/60 mi bodha 2,867 14's STIBL. 34.80/10's SUBL 1.68/10's 57/EL 4.82 404 (E) dt. 10.05.2001 8 84/histories 9.58/18.gm 706/5ml 772 (E) dt. 10 04 2012 (8,09) 611 (E) d) 27.05.2003 769/E) dt 19.05.2006 (13.33) 885(E) dt 19,04.2010 73(E) dt. 10:04:2013 789(E) dt. 10.04.2012 789(E) dt. 10.04.2012 (5.45) 1953(E) 41.45.06.2009 3027(E) dt. 23.12.2010 392(E) dt. 28.04.2011 76.40| 1969|D|41.13.08.2009 SO No. & Date 38200 dt. 24.04.2011 Annexure A. % change as as compared to DPCC'56 (5.58) 909 Ceiling Price under DPCD = 1986; Inct. to E.D.) (Rav Pack) 220 8 0.16 100 4 00 88 88 138 0.25 Ceiling price under DPCO 1896 (Exot. E.D.) (Re/ unit) 880 0.62 888 8 20 0.52 0.20 7 28.82 0 0 0 5.75% 8850 9000 28.41% 90000 100 30.77% 11.81% 8.29% 200% 7,76% 2.08% 14.66% Lowest PTR (Ra-Abelt) 6.98 172 0.43 0.12 990 3,00 0 to 0 Highest PTR (Ra/unit) 0,85 80 8 1.73 0.48 1.27 0.15 0.26 2 Proposed Ceiling Price under DPCD 2013 excluding local taxes (Rsipack) Section 3 – Architectual Activation Legislation and Architecture Legislation L Saction: 2 - Analgaelice, Antilyredice, Nocesteroldal Anti-infarmentery Medicines, Wedicines used to treat dour 2.4 Disease modifying operas used in Resumantial disordery 5.4 Disease modifying operas used in Resumantial disordery 5.0 mg 8.5 Sec. 5.4 Sec. 0.16 8 200 0.62 0.21 130 3.60 0.43 Summary of Prices worked out based on Data furnished by IMS-hisalth/Companies 500 mg + 25 mg 100 mg+25 mg Strengths 4 mg Zmg/Sni 200,gpiese 4 month 0.06% 20 mg 0.30% Section: 21 - Ophehalmological Preparations Section: 25 - Medicines acting on the respiratory tract 21.1: Anti-Infective agents Route of Atministration Cases Forts Covern / Ontreor Hemerathagon Opergonias P.S.T. (Section in Redicines T.A.) Anadols and other families resistent T.A. Anadols and other families resistent Section: 9 -Antiparkinsonism medicines Drops P.S.T. Syruc A.S.3 Antimalarial Medicinas 25.1: Antisalhmetic medicines 0.5.3,1 For curative treatment 13.3; Anti-filammatory and antiprumite P.S.T Dro 22.2: Antiosytocics Category P.S.T P.S.T P.B.T P,5,T Cprofesson Hydrochlands Levodopa+ Carbidops Sabutansi Suphase Sabutansi Suphase Sabutansi Suphase Betamothasona

.

0

-